By CAFMI AI From JAMA
Metformin Significantly Reduces Knee Osteoarthritis Pain
Knee osteoarthritis (OA) is a prevalent cause of disability worldwide, strongly influenced by overweight and obesity, conditions that contribute to disease development and progression via metabolic pathways. Traditional treatments offer limited symptom relief and do not address underlying metabolic dysfunction. This pivotal randomized, double-blind, placebo-controlled trial conducted across multiple U.S. centers from 2023 to 2025 provides robust evidence that metformin, a widely used metabolic modulator, effectively reduces pain and improves physical function in patients with knee OA who are overweight or obese. The study enrolled 800 adults aged 40 to 75 years, all with clinical and radiographic evidence of knee OA and a BMI of at least 25. Participants were randomly assigned to receive either 1500 mg of metformin daily or placebo over 24 months. Results demonstrated a statistically significant reduction in the primary outcome measure, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale, favoring the metformin group by a mean difference of -1.8 points at 24 months, with a confidence interval from -2.5 to -1.1 (p<0.001). Secondary outcomes including total WOMAC score and physical function measures also improved significantly with metformin compared to placebo. These findings highlight metformin’s potential to alleviate symptoms in this challenging patient population, supporting its role beyond glucose control to potentially repurposing in metabolic regulation of OA pain and impairment.
Metformin Slows Joint Damage and Supports Weight Loss in OA
Beyond symptomatic relief, the trial’s imaging data revealed that metformin may modify the structural progression of knee OA. MRI assessments demonstrated that patients treated with metformin experienced markedly slower cartilage loss compared to the placebo group over two years. This structural preservation is a crucial advancement, as cartilage degradation is a hallmark of OA progression, often leading to irreversible joint damage and disability. Alongside these skeletal benefits, patients receiving metformin lost an average of 3.2 kg, whereas those on placebo showed a slight weight gain of approximately 0.6 kg. Weight reduction is a recognized critical factor in managing knee OA, as excess body mass increases joint load and metabolic inflammation. The dual benefit of pain reduction and weight loss positions metformin as a multifaceted therapeutic agent addressing both symptomatic and disease-modifying aspects of OA in overweight populations. These effects are consistent with the drug’s known mechanisms influencing systemic metabolism and inflammation, which may underlie the improvements documented in both clinical and structural outcomes.
Clinical Implications and Future Directions for Metformin in OA Care
Safety data from this large-scale study were encouraging, with metformin’s adverse events primarily consisting of mild gastrointestinal symptoms and no significant increase in serious adverse events compared to placebo. This favorable safety profile combined with demonstrated efficacy suggests metformin could be integrated safely into clinical practice for knee OA management in patients with overweight or obesity. For primary care clinicians and rheumatologists, these findings may inform a shift toward metabolic-centered OA treatment strategies, adding a valuable option that tackles both symptoms and disease progression. Clinicians should consider patient selection carefully and monitor for gastrointestinal tolerance when prescribing metformin. Counseling points include discussing potential benefits in pain relief, function, and joint preservation, as well as realistic expectations regarding weight loss magnitude and long-term outcomes. Follow-up should include symptom monitoring, imaging as indicated, and adjustments based on tolerability and efficacy. While these findings are promising, further large-scale, longer-term studies are warranted to confirm sustained benefits and assess possible impacts on surgical intervention rates and quality of life. Nonetheless, this study marks an important step in expanding OA therapeutic paradigms to include metabolic modulation, emphasizing the need for a multidisciplinary approach given the interplay of obesity, metabolism, and joint health.
Read The Original Publication Here
